Drug intelligence / Profile preview

Kinezodianone R hydrochloride

Development stage: Phase 2
Lead developer: Théa Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

Kinezodianone R hydrochloride (T-4090) is a small molecule drug in development for the treatment of open-angle glaucoma and ocular hypertension. It is being developed as an ophthalmic solution and is currently in Phase 2 clinical trials. The drug acts as a Rho kinase (ROCK) inhibitor, targeting the trabecular meshwork to increase aqueous humor outflow and lower intraocular pressure—a key mechanism for managing glaucoma. The developer and sponsor of this compound is Laboratoires Théa SAS[1][2][3][7].

Brand names: T4090T-4090T 4090
Other names: kinezodianone r hclt-4090t4090t 4090

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on Kinezodianone R hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinezodianone R hydrochloride.

Explore the full profile